Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
Artiva Biotherapeutics Inc ARTV
$6.99
▼ -6.68%
($-0.50)
⬇️ Below Yest. Low
🎢 High Beta
Open
$7.48
Prev Close
$7.49
Day Range
$6.90 – $7.49
52W Range
$2.52 – $14.53
Market Cap
$341.74M
Beta
5.95
EPS (TTM)
$-3.43
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-07-19 |
| Shares Out. | 48,590,000 |
| Website | artivabio.com/ ↗ |
| Phone | 18582674467 |
| Employees | 115 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$25.0M |
| Free Cash Flow | -$76.9M |
| Total Assets | $368.6M |
| Total Liabilities | $21.1M |
| Equity | $347.5M |
About Artiva Biotherapeutics Inc
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Artiva Biotherapeutics Inc is a publicly traded company under the ticker symbol ARTV on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-09-01)